Feasibility and Acceptability of Personalized Breast Cancer Screening (DECIDO Study): A Single-Arm Proof-of-Concept Trial

Int J Environ Res Public Health. 2022 Aug 21;19(16):10426. doi: 10.3390/ijerph191610426.

Abstract

The aim of this study was to assess the acceptability and feasibility of offering risk-based breast cancer screening and its integration into regular clinical practice. A single-arm proof-of-concept trial was conducted with a sample of 387 women aged 40-50 years residing in the city of Lleida (Spain). The study intervention consisted of breast cancer risk estimation, risk communication and screening recommendations, and a follow-up. A polygenic risk score with 83 single nucleotide polymorphisms was used to update the Breast Cancer Surveillance Consortium risk model and estimate the 5-year absolute risk of breast cancer. The women expressed a positive attitude towards varying the frequency of breast screening according to individual risk and, especially, more frequently inviting women at higher-than-average risk. A lower intensity screening for women at lower risk was not as welcome, although half of the participants would accept it. Knowledge of the benefits and harms of breast screening was low, especially with regard to false positives and overdiagnosis. The women expressed a high understanding of individual risk and screening recommendations. The participants' intention to participate in risk-based screening and satisfaction at 1-year were very high.

Keywords: acceptability; breast cancer; feasibility; personalized screening; polygenic risk; proof-of-concept; risk assessment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms* / diagnosis
  • Breast Neoplasms* / genetics
  • Early Detection of Cancer*
  • Feasibility Studies
  • Female
  • Humans
  • Mammography
  • Mass Screening
  • Proof of Concept Study

Associated data

  • Dryad/10.5061/dryad.q83bk3jmc

Grants and funding

This research was funded by INSTITUTO DE SALUD CARLOS III, grant number PI17/00834 and co-funded by Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa”, with the support of the Lleida Biomedical Research Institute (IRBLleida) and the CERCA Programme/Generalitat de Catalunya. C.L.V received a grant from the Santander Predoc Program scholarship in 2020 as a predoctoral fellow at the University of Lleida (Agreement 87/2020 of the Consell de Govern, Universitat de Lleida, of 28 April 2020). The non-profit organization Oncolliga Lleida funded part of the genomic analyses for the breast cancer risk assessment. The publication of this article was partly funded by the non-profit women’s breast cancer support association ADIMA Lleida.